BBI-355

Boundless Bio, Inc. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BBI-355
Sponsor	Boundless Bio, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BBI-355 CI brief — competitive landscape report
BBI-355 updates RSS · CI watch RSS
Boundless Bio, Inc. portfolio CI